Wolverine Trading
LCTX icon

Wolverine Trading’s Lineage Cell Therapeutics LCTX Stock Holding History

Wolverine Trading’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,000
Closed -$38K – 6634
2021
Q2 		$38K Buy
13,000
+2,300
+21% +$5.95K ﹤0.01% 5641
2021
Q1 		$24K Buy
+10,700
New +$25.7K ﹤0.01% 5742
2019
Q3 		– Sell
-10,500
Closed -$12K – 4722
2019
Q2 		$12K Sell
10,500
-7,900
-43% -$9.1K ﹤0.01% 4304
2019
Q1 		$24K Buy
+18,400
New +$22.9K ﹤0.01% 4391
2018
Q4 		– Sell
-22,746
Closed -$47K – 4948
2018
Q3 		$47K Buy
22,746
+6,058
+36% +$12.7K ﹤0.01% 4714
2018
Q2 		$39K Hold
16,688
– – ﹤0.01% 4946
2018
Q1 		$39K Buy
+16,688
New +$39.1K ﹤0.01% 4946
2017
Q4 		– Sell
-21,831
Closed -$54K – 5225
2017
Q3 		$54K Sell
21,831
-915
-4% -$2.27K ﹤0.01% 4216
2017
Q2 		$63K Buy
22,746
+10,287
+83% +$28.7K ﹤0.01% 4006
2017
Q1 		$36K Buy
+12,459
New +$35.4K ﹤0.01% 4045
2016
Q3 		– Sell
-15,316
Closed -$34K – 4858
2016
Q2 		$34K Buy
+15,316
New +$37.6K ﹤0.01% 3860

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wolverine Trading's LCTX Position: Q3 2021 in Review

Wolverine Trading sold out of Lineage Cell Therapeutics (LCTX) in Q3 2021, closing a stake of 13,482 shares — an estimated $34.6K sold.

Wolverine Trading first reported a position in LCTX in Q2 2016 and held it in 11 quarters. The position peaked at $61K in Q4 2017. 115 funds tracked by Wall St. Rank hold LCTX as of Q3 2021.

  • Wolverine Trading reported no remaining Lineage Cell Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Wolverine Trading sold 13,482 Lineage Cell Therapeutics shares in Q3 2021, an estimated $34.6K.
  • Wolverine Trading first reported a position in Lineage Cell Therapeutics in Q2 2016 and held it in 11 quarters.
  • Wolverine Trading's Lineage Cell Therapeutics position peaked at $61K in Q4 2017.
  • 115 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2021.

Based on Wolverine Trading's 13F filing for Q3 2021, filed 12 Nov 2021.